The second study (NCT03774654) is exploring whether donor-derived NKT cells transduced with a vector codifying for the anti-CD19 chimeric receptor (containing CD28 as a costimulatory domain and IL-15 improving in vivo persistence) might help in patients with CD19+ lymphoma or leukemia (Table 1). Here, CD19 is linked to leukemia.